Valink Therapeutics, founded with a mission to revolutionize cancer treatment, focuses on developing next-generation antibody-based therapeutics. The company specializes in discovering bispecific antibody drug-conjugates (BsADC) targeting solid tumors that are poorly addressed by current immunotherapies. By incorporating multiple antibody modifications simultaneously, Valink Therapeutics rapidly and scalably generates complex drug candidates with bi-/multispecificity, multivalency, and drug-conjugation.

Notable figures affiliated with Valink Therapeutics include leading scientists and industry experts in oncology and biotechnology. The company has secured investments from prominent venture capital firms specializing in life sciences. Key achievements include the successful identification of novel mechanisms of action from known targets and the development of promising therapeutic candidates. Valink Therapeutics' innovative approach has the potential to significantly impact the treatment landscape for solid tumors, offering new hope for patients with limited options.